What's new? Log in Free sign up

ProQR Therapeutics (PRQR)

Company Profile

Company profile

Ticker

PRQR

Exchange

Website

CEO

Mr. Daniel Anton de Boer

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

ProQR Therapeutics B.V.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

PRQR stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$9.33

Low target

$4.00

High target

$14.00

Chardan Capital

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Current report (foreign) (amended)

Current report (foreign)

Current report (foreign)

Current report (foreign)

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Notice of effectiveness

Prospectus supplement for primary offering

Current report (foreign)

Latest ownership filings

View all

VAN HERK INVESTMENTS B.V.

VAN HERK INVESTMENTS B.V.

VAN HERK INVESTMENTS B.V.

RTW INVESTMENTS, LP

Stichting Aescap Life Sciences

ADAGE CAPITAL PARTNERS GP, L.L.C.

GOLDMAN SACHS GROUP INC

WELLINGTON MANAGEMENT GROUP LLP

Financial summary

Financial statements Chart PRQR financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2024

PRQR institutional ownership history Ownership history

50.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	31	12	+158.3%
Opened positions	21	5	+320.0%
Closed positions	2	2	–
Increased positions	1	1	–
Reduced positions	2	1	+100.0%

13F shares	Current	Prev Q	Change
Total value	24.50 bn	12.78 bn	+91.7%
Total shares	41.07 mm	31.87 mm	+28.8%
Total puts	8.60 k	0.00	NEW
Total calls	26.20 k	16.50 k	+58.8%
Total put/call ratio	0.3	–	–

Largest owners	Shares	Value	Change
LLY Eli Lilly and	13.37 mm	$22.06 mm	0.0%
Fund Management B.V. Privium	5.58 mm	$9.21 bn	+4.4%
Stichting Aescap 2.0	5.34 mm	$0.00	0.0%
Van Herk Investments B.V.	4.28 mm	$6.85 mm	0.0%
Adage Capital Partners GP, L.L.C.	3.63 mm	$6.02 bn	NEW
Goldman Sachs & Co	3.30 mm	$13.85 mm	0.0%
EcoR1 Capital	2.04 mm	$3.39 bn	NEW
DAFNA Capital Management	905.58 k	$1.50 bn	NEW
Ghost Tree Capital	900.00 k	$1.49 bn	NEW
Ikarian Capital	483.58 k	$802.75 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Adage Capital Partners GP, L.L.C.	3.63 mm	+3.63 mm	NEW
EcoR1 Capital	2.04 mm	+2.04 mm	NEW
DAFNA Capital Management	905.58 k	+905.58 k	NEW
Ghost Tree Capital	900.00 k	+900.00 k	NEW
Ikarian Capital	483.58 k	+483.58 k	NEW
Deutsche Bank AG - Registered Shares	385.15 k	+385.15 k	NEW
Fund Management B.V. Privium	5.58 mm	+236.28 k	+4.4%
Millennium Management	148.36 k	+148.36 k	NEW
Two Sigma Advisers	131.50 k	+131.50 k	NEW
Squarepoint Ops	84.73 k	+84.73 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $8 price target.

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $10 price target.

ProQR Receives $9.1M to Develop RNA Therapy for Rett Syndrome, Impacting 350,000 People

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Press releases

From Benzinga Pro

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced

ProQR Announces Third Quarter 2024 Operating and Financial Results

AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.